Hospira acquires Orchid's penicillin and penems API business
This article was originally published in Scrip
Hospira is acquiring Orchid Chemicals & Pharmaceuticals' penicillin and penem active pharmaceutical ingredients (API) business and Indian facility together with the associated process R&D infrastructure for about $200 million, with an eye on vertical integration aspects and securing API supplies.
You may also be interested in...
Eris Lifesciences has acquired a Novartis trademark for vildagliptin, a DPP-4 inhibitor that has been the subject of a torrent of alleged infringement-related legal action in India. Pricing for the acquired brand will be interesting to watch from now on as a patent on vildagliptin is set to expire soon.